NDAORALTABLET
Approved
Dec 1958
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
DIUPRES-250 (chlorothiazide; reserpine) by Merck & Co. is clinical pharmacology: the mechanism of the antihypertensive effect of thiazides is unknown. Approved for pregnancy, just, heart failure and 2 more indications. First approved in 1958.
Drug data last refreshed 13h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DIUPRES-250 is a fixed-dose combination of chlorothiazide (a thiazide diuretic) and reserpine (an antihypertensive) for oral use, approved in 1958 by Merck & Co. It reduces blood pressure by promoting sodium and chloride excretion in the kidneys and vasodilation. The product is indicated for hypertension and heart failure management.
LOE Approaching
Product nearing end of life with minimal linked job openings; legacy franchise with limited expansion opportunity.
Mechanism of Action
CLINICAL PHARMACOLOGY: The mechanism of the antihypertensive effect of thiazides is unknown. Chlorothiazide does not usually affect normal blood pressure. Chlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosage all thiazides are…
Indications (5)
Worked on DIUPRES-250 at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.